Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The business had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.17 million. Lexicon Pharmaceuticals had a negative return on equity of 108.54% and a negative net margin of 8,311.12%. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Lexicon Pharmaceuticals Trading Down 2.6 %
Shares of NASDAQ:LXRX traded down $0.06 during trading on Tuesday, hitting $2.24. The company’s stock had a trading volume of 1,066,964 shares, compared to its average volume of 3,647,052. The business has a 50 day moving average price of $1.83 and a two-hundred day moving average price of $2.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on LXRX
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
- Five stocks we like better than Lexicon Pharmaceuticals
- How Technical Indicators Can Help You Find Oversold StocksĀ
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Where Do I Find 52-Week Highs and Lows?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- What Does Downgrade Mean in Investing?
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.